Navigation Links
Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
Date:8/3/2009

BEIJING, Aug. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers have received their first shot of the vaccine and, during the three-day observation of safety, the preliminary tests on the A/H1N1 influenza vaccine have indicated that the vaccine is safe and reliable in humans.

The clinical trial began on July 22, 2009 and a total of 1,614 volunteers, including 101 elders, 706 adults, 404 juvenile and 403 children, had received the first shot of the vaccine through July 25. During the three-day safety observation period, none of the volunteers participating in Sinovac's clinical tests exhibited any signs of severe adverse reactions. Total adverse event rate is 11.8%, which is similar to seasonal influenza vaccine. The adverse events were all mild and transient. The most common symptom is pain at the site of injection.

This clinical trial is organized by China's Center for Disease Control (CDC), and undertaken by Beijing CDC. The Ministry of Health (MOH) and State Food and Drug Administration (SFDA) are paying great attention to this clinical trial. Deputy Director General of MOH Disease Control Department, Donglou Xiao, Director of SFDA Registration Section, Wei Zhang, and other relevant experts visited the clinical site to inspect the clinical study. In June 2009, Sinovac announced that the Ministry of Health had made an initial order of 4 million doses of Panflu, which is expected to be delivered by the end of September.

As usual, Sinovac's seasonal influenza vaccine has been released by China SFDA and officially launched to the market at the end of July 2009.

About Sinovac

Sinovac Biotech Ltd. is a China
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Closes $9.75 Million Private Placement
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
9. Sinovac Biotech Holds Annual General Meeting
10. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
11. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... SAN ANTONIO , Dec. 12, 2014 /PRNewswire/ ... presentation of data at the San Antonio Breast Cancer ... epoetin alfa plus best supportive care (BSC) versus BSC ... breast cancer receiving standard chemotherapy. This non-inferiority trial did ... out a 15 percent or greater increase in the ...
(Date:12/12/2014)... (PRWEB) December 11, 2014 Graphite Metallizing ... materials for pumps and process equipment, has appointed Kirk ... States and Ontario, Canada. Staller holds a B.S. degree ... in the industrial market place, much of it with ... out of his Michigan office. , “We are ...
(Date:12/12/2014)... Electronic Data Interchange (EDI) has ... and supply chain management to depend from paper ... benefits associated with the use of EDI such ... has helped improve the acceptance of this technology ... data tables and 107 figures spread through 210 ...
(Date:12/12/2014)... 2014 LayerBio is an MIT ... and wound care applications. The National Science ... business innovation research grant to support development of ... leading cause of irreversible blindness worldwide. In the ... from glaucoma. The typical first-line treatment for ...
Breaking Biology Technology:Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12Kirk Staller Joins Graphite Metallizing Corporation 2The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 2The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 3The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets 4MIT Spinoff Receives NSF Grant to Develop Nanoparticle Glaucoma Therapy 2
... Than rituximab ... in a Pre-Clinical Study, ... that ofatumumab (HuMax-CD20(R)) appeared more,effective at inducing complement dependent cytotoxicity ... study. The CD20,antibodies were incubated with tumor cells and analyzed ...
... Prize winner Richard Feynman presented a talk entitled There,s Plenty ... was no physical reason why humans couldn,t manipulate atoms. ... the new atom positions remains. How do you know ... 7, 2007 issue of Science, IBM and Imago have taken ...
... Chief Financial Officer and James Weaver as Chairman, ... ILI ) announced today that Thomas Gerson has been ... Weaver as,Chairman of the Board of Directors. In addition, ... and Development. "We are pleased to welcome Tom ...
Cached Biology Technology:Genmab Announces Encouraging Preclinical Data for ofatumumab 2IBM and Imago find a crucial difficulty in semiconductor device scaling 2Interleukin Genetics Announces Management and Board Appointments 2Interleukin Genetics Announces Management and Board Appointments 3Interleukin Genetics Announces Management and Board Appointments 4
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... NEW YORK , Nov. 19, 2014  Earlier ... Board at New York College, and one of the ... for biosensor signals that are transmitted from Smartphones to ... there were Smartphones and has one of the earliest ... are discussing its usage in the military, child care, ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... Six researchers from the Technische Universitaet Muenchen are ... bring around ten million euros to support pioneering ... investigate the impact of extreme weather events on ... magnetic vortices for enhanced data processing. Prof. Rdiger ...
... among South Asians to be recalculated has been published by ... from the University,s Departments of Health Sciences and Cardiovascular Sciences ... Asians should be classed as obese to be redefined. ... a journal of the Public Library of Science. South ...
... 2004 as a three-person start-up may well be on ... Advanced by a team of young Dutch scientists pushing ... is attracting the attention of some key investors and ... to innovative SMES, with the Eurostars funding programme leading ...
Cached Biology News:10 million euros for pioneering research projects at TU Muenchen 210 million euros for pioneering research projects at TU Muenchen 310 million euros for pioneering research projects at TU Muenchen 410 million euros for pioneering research projects at TU Muenchen 510 million euros for pioneering research projects at TU Muenchen 610 million euros for pioneering research projects at TU Muenchen 7New research calls for lower limit to be set for South Asian obesity level 2Biotech start-up brings DNA-sequencing to the medical market 2Biotech start-up brings DNA-sequencing to the medical market 3
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
... GCpro Taq DNA Polymerase is a versatile ... for all PCR applications. GCpro Taq DNA ... expressed in E. coli, containing the DNA ... enzyme includes a highly processive 5'-3' DNA ...
Ps-Aeruginosa (IgG) -Ab EIA Sample Size: 100 l...
...
Biology Products: